Company / Cash & Equivalents
Steris Cash & Equivalents History
FY2016-FY2021 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$220.5M
FY2021
5-year range
$220.5M / $220.5M
FY2017-FY2021
Trend
-31.0%
vs FY2020
Sector context
#83 of 152
Health Care
What the data says
At $221M, Steris's cash & equivalents ranks #83 of 152 in the Health Care sector. Cash & Equivalents has fluctuated over the past 6 years, ranging from $202M in FY2018 to $320M in FY2020.
Based on SEC 10-K filings.
$221M in FY2021 with a 5-year CAGR of -2.4%.
Remained stable around $221M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +3.0%
- 5-Year CAGR
- -2.4%
- 10-Year CAGR
- -
Sector benchmark
#83 of 152 in Health CareTop 55% of 152This company $220.5M Sector average $1.2B
▼
-81.1% below sector average
Key checks
Key Insights
- 5-year CAGR of -2.4%, indicating a declining trend.
- In FY2021, cash & equivalents decreased 31.0% year-over-year.
- Ranks #83 out of 152 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 1.06 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | $220.5M | -31.0% |
| FY2020 | $319.6M | +44.8% |
| FY2019 | $220.6M | +9.5% |
| FY2018 | $201.5M | -28.8% |
| FY2017 | $282.9M | +13.7% |
| FY2016 | $248.8M | - |
As of FY2021 · SEC 10-K · Updated Mar 13, 2026